A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma (XL092-201)
Clinical Trial Grant
Awarded By
Exelixis, Inc
Start Date
April 15, 2026
End Date
April 14, 2031
Awarded By
Exelixis, Inc
Start Date
April 15, 2026
End Date
April 14, 2031